Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETER-SMM: Daratumumab + Lenalidomide + Dexamethasone in Smoldering Myeloma
NCT03937635Phase 3Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Sep 2019
- Primary completion
- Dec 2029
- Countries
- 2
01
Overview
A Phase 3 trial of daratumumab in smoldering multiple myeloma (SMM), sponsored by ECOG-ACRIN Cancer Research Group. Started Sep 2019; status: recruiting.
02
Drugs
daratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03937635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937635.